jmg.bmj29d
Advancing in Schaaf-Yang syndrome pathophysiology: from bedside to subcellular analyses of truncated MAGEL2
Background Schaaf-Yang syndrome (SYS) is caused by truncating mutations in MAGEL2, mapping to the Prader-Willi region (15q11-q13), with an ... and Hospital Sant Joan de Déu (PIC-111-19). We would like ...
Endocrinology Advisor1d
Vykat XR Approved to Treat Hyperphagia in Prader-Willi Syndrome
The FDA has approved Vykat XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years ...
News-Medical.Net on MSN16h
US FDA approves first treatment for hyperphagia in Prader-Willi syndrome
The United States Food and Drug Administration (US FDA) has approved VYKAT™ XR, a significant milestone as the first approved treatment for hyperphagia in Prader-Willi syndrome (PWS).
BioPharma Dive7d
First Prader-Willi drug to reduce hunger approved by FDA
Clearance of Vykat unlocks what analysts anticipate will be a lucrative market opportunity for Soleno Therapeutics.
Disability Scoop6d
FDA Green-Lights First Treatment For Prader-Willi Syndrome
Federal regulators are clearing a first-of-its-kind treatment for symptoms of a rare neurodevelopmental disorder that is ...
Healio6d
FDA approves first therapy to treat hyperphagia in Prader-Willi syndrome
The FDA has approved the first therapy to address hyperphagia for children and adults aged 4 years and older with ...
US FDA approves first treatment for rare genetic disorder Prader-Willi syndrome
The U.S. Food and Drug Administration on Wednesday approved Soleno Therapeutics' drug to treat a rare genetic disorder, ...
MedPage Today on MSN6d
FDA OKs First Drug for Hyperphagia in Prader-Willi Syndrome
Diazoxide choline is the first drug indicated for hyperphagia in the rare genetic disorder. Prior to approval, people with ...
Monthly Prescribing Reference6d
Vykat XR Approved to Treat Hyperphagia in Prader-Willi Syndrome
Credit: Solano Therapeutics. Vykat XR contains an extended-release formulation of diazoxide choline, the crystalline salt of diazoxide. Vykat XR is expected to be available in April 2025.